Bispecific SPR analysis

Bispecific antibody based therapeutics have become increasingly popular thanks to their greater ability to target and engage the immune system in the fight against cancer.

Due to evidence that simultaneous administration of two mAbs against autoimmune diseases has been shown to increase the risk of potentially fatal side effects without increasing the efficiency of the treatment there has been a major drive to develop BsAbs and novel bispecific molecules which can combine two antigen binding sites and provide a decreased risk of side effects whilst offering increased therapeutic potential

The foundation for most BsAbs is one antigen binding site that binds the CD3 receptor, which activates the cytotoxic T lymphocytes, and another antigen site that binds a tumour specific antigen and promotes the destruction of tumour cells:

Tumour specific antigen we can support

CD19
CD20
CD33
CD123
HER2
EpCAM
BCMA
CEA
TNF, IL1, IL4, IL14, IL17, IL23

Antibody Analytics have developed a novel suite of SPR assays to assess your molecule in a multitude of ways no matter what flavour your bispecific comes in. These assays will provide data so that you can have confidence that your molecule is performing as expected.

Which assay format is right for you?

Independent antigen binding (IAB)

  • IAB assessment of each antigen binding site allows you to screen a large number of potential antibodies against a target at an early stage, enabling rapid identification of potential candidates and importantly, their kinetic rate constants and affinity.

Dependent antigen binding (DAB)

  • DAB assessment is best used to ensure that sequential binding of antigens does not affect the affinity observed in IAB. For example if pre-binding of antigen 1 decreases the affinity of antigen 2 then the molecule may not perform as expected in vivo.

Potential effector function effects

  • There is an increasing body of evidence that indicates that binding of an antigen to the FAb region causes a conformational change in antibodies that can lead to an increased affinity for the Fcγ receptors.

With a wealth of experience characterising not only the binding, but function of bi and trispecific antibody products, from discovery through to lot release, why not get in touch to discuss your requirements

Developing a CD3 engager? We can support those too...

Contact us